Drug-induced autoimmunity

Best Practice and Research: Clinical Rheumatology

Volumn 18, Issue 5 SPEC. ISS., 2004, Pages 677-688

  Olsen, Nancy J ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adverse effects; Autoantibodies; Autoimmune diseases; Drug induced lupus; Therapeutics

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; ATORVASTATIN; AUTOANTIBODY; CRYOGLOBULIN; CYCLOSPORIN; CYTOKINE; DNA ANTIBODY; ERYTHROMYCIN; ETANERCEPT; HISTONE ANTIBODY; HLA ANTIGEN CLASS 1; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN M ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTEGRIN; METHOTREXATE; MEVINOLIN; MINOCYCLINE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROCAINAMIDE; PROTEIN BCL 2; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SIMVASTATIN; SULFANILAMIDE DERIVATIVE; T LYMPHOCYTE RECEPTOR; UNINDEXED DRUG;

ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL TRIAL; CROHN DISEASE; CROSS REACTION; DEMYELINATING DISEASE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DNA METHYLATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG EXPOSURE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG WITHDRAWAL; GLOMERULONEPHRITIS; HEPATITIS C; HEREDITY; HUMAN; HYPERLIPIDEMIA; IDIOPATHIC DISEASE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LOEFFLER PNEUMONIA; LUPUS ERYTHEMATOSUS; MITOCHONDRIAL MYOPATHY; MYALGIA; MYOPATHY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY FAILURE; RHEUMATOID ARTHRITIS; RISK FACTOR; SERUM SICKNESS; SPONDYLOARTHROPATHY; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; THYMUS; VASCULITIS;

EID: 9244229071     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2004.05.006     Document Type: Article

References (38)

1. Brogan B.L. Olsen N.J. et al. Drug-induced rheumatic syndromes Current Opinion in Rheumatology 15 2003 76-80
2. van Oosten B.W. Barkhof F. Truyen L. Boringa J.B. et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2 Neurology 47 1996 1531-1534
3. Mohan N. Edwards E.T. Cupps T.R. Oliverio P.J. et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides Arthritis and Rheumatism 44 2001 2862-2869
4. Thomas C.W. Weinshenker B.G. & Sandborn W.J. Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's Disease Inflammatory Bowel Disease 10 2004 28-31
5. Pisetsky D.S. Tumor necrosis factor alpha blockers and the induction of anti-DNA autoantibodies Arthritis and Rheumatism 43 2000 2381-2382
6. Cush J.J. & Goldings E.A. Drug-induced lupus: Clinical spectrum and pathogenesis American Journal of the Medical Sciences 290 1985 36-45
7. Kale S.A. Drug-induced systemic lupus erythematosus. Differentiating it from the real thing Postgraduate Medicine 77 1985 231.9-242.9
8. Lepore L. Marchetti F. Facchini S. Leone V. et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis Clinical and Experimental Rheumatology 21 2003 276-277
9. Lipsky P.E. van der Heijde D.M. St Clair E.W. & Furst D.E. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group New England Journal of Medicine 343 2000 1594-1602
10. Charles P.J. Smeenk R.J. De Jong J. Feldmann M. et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: Findings in open-label and randomized placebo-controlled trials Arthritis and Rheumatism 43 2000 2383-2390
11. De Rycke L. Kruithof E. Van Damme N. & Hoffman I.E. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy Arthritis and Rheumatism 48 2003 1015-1023
12. Woosley R.L. Drayer D.E. Reidenberg M.M. Nies A.S. et al. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome New England Journal of Medicine 298 1978 1157-1159
13. Burlingame R.W. & Cervera R. Anti-chromatin (anti-nucleosome) autoantibodies Autoimmunity Reviews 1 2002 321-328
14. Morel L. & Wakeland E.K. Lessons from the NZM2410 model and related strains International Reviews in Immunology 19 2000 423-446
15. Srivastava M. Rencic A. Diglio G. Santana H. et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus Archives in Dermatology 139 2003 45-49
16. Carlson E. & Rothfield N. Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis Arthritis and Rheumatism 48 2003 1165-1166
17. Wilson L.E. Widman D. Dikman S.H. & Gorevic P.D. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection Seminars in Arthritis and Rheumatism 32 2002 163-173
18. Bruyn G.A. Veenstra R.P. Halma C. & Grond J. Anti-glomerular basement membrane antibody-associated renal failure in a patient with leflunomide-treated rheumatoid arthritis Arthritis and Rheumatism 48 2003 1164-1165
19. Sethi S. Sahani M. & Oei L.S. ANCA-positive crescentic glomerulonephritis associated with minocycline therapy American Journal of Kidney Disease 42 2003 E27-E31
20. Colombel J.F. Loftus E.V. Jr Tremaine W.J. Egan L.J. et al. The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients Gastroenterology 126 2004 19-31
21. Kretz-Rommel A. Duncan S.R. & Rubin R.L. Autoimmunity caused by disruption of central T cell tolerance. A murine model of drug-induced lupus Journal of Clinical Investigation 99 1997 1888-1896
22. Kretz-Rommel A. & Rubin R.L. Disruption of positive selection of thymocytes causes autoimmunity Nature Medicine 6 2000 298-305
23. Deng C. Lu Q. Zhang Z. Rao T. et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling Arthritis and Rheumatism 48 2003 746-756
24. Richardson B. DNA methylation and autoimmune disease Clinical Immunology 109 2003 72-79
25. von Greyerz S. Bultemann G. Schnyder K. Burkhart C. et al. Degeneracy and additional alloreactivity of drug-specific human alpha beta(+) T cell clones International Immunology 13 2001 877-885
26. Pichler W.J. Drug-induced autoimmunity Current Opinion in Allergy and Clinical Immunology 3 2003 249-253
27. Vermeire S. Noman M. Van Assche G. Baert F. et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: A prospective cohort study Gastroenterology 125 2003 32-=39
28. Sandborn W.J. Feagan B.G. Hanauer S.B. Present D.H. et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial Gastroenterology 120 2001 1330-1338
29. Gough A. Chapman S. Wagstaff K. Emery P. et al. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome British Medical Journal 312 1996 169-172
30. van de Putte L.B. Rau R. Breedveld F.C. Kalden J.R. et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: A 12 week, phase II study Annals of the Rheumatic Diseases 62 2003 1168-1177
31. Jarrett S.J. Cunnane G. Conaghan P.G. Bingham S.J. et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: Case series Journal of Rheumatology 30 2003 2287-2291
32. Fleischmann R.M. Schechtman J. Bennett R. Handel M.L. et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial Arthritis and Rheumatism 48 2003 927-934
33. Baeten D. Kruithof E. Van den B.F. Van den B.N. et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: A new perspective on the role of host defence in the pathogenesis of the disease? Annals of the Rheumatic Diseases 62 2003 829-834
34. Ucar M. Mjorndal T. & Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity Drug Safety 22 2000 441-457
35. Thompson P.D. Clarkson P. & Karas R.H. Statin-associated myopathy Journal of the American Medical Association 289 2003 1681-1690
36. Diaczok B.J. & Shali R. Statins unmasking a mitochondrial myopathy: A case report and proposed mechanism of disease Southern Medical Journal 96 2003 318-320
37. Parmar B. Francis P.J. & Ragge N.K. Statins, fibrates, and ocular myasthenia Lancet 360 2002 717
38. Engel W.K. Reversible ocular myasthenia gravis or mitochondrial myopathy from statins? Lancet 361 2003 85-86